25 Jul 2018 --- Lonza has updated its outlook for the full year after reporting 8.2 percent organic (like-for-like) sales growth, double-digit organic CORE EBITDA and CORE EBIT growth during the first half of 2018. The company attributes growth to the successful integration of Capsugel and “buoyant demand” from pharmaceutical and biotech clients for products including viruses for gene therapy.
.jpg)
